Skip to main content
. 2017 Jul 6;358:j2941. doi: 10.1136/bmj.j2941

Table 3.

Risk of mortality associated with benzodiazepine initiation versus non-initiation in high dimensional propensity score matched sensitivity and subgroup analyses

Analysis Benzodiazepine initiators Benzodiazepine non-initiators Hazard ratio (95% CI)
No of patients No of Events Person years Incidence/1000 person years No of patients No of events Person years Incidence/1000 person years
Follow-up duration (months):
 12 1 252 988 7671 986 396 7.8 1 252 988 6552 855 316 7.7 1.04 (1.01 to 1.08)
 48 1 252 988 13 532 2 241 015 6.0 1 252 988 10 299 1 696 159 6.1 1.05 (1.02 to 1.07)
Patient age (years):
 <65 1 156 209 2160 504 932 4.3 1 156 209 1843 462 811 4.0 1.09 (1.02 to 1.15)
 ≥65 92 273 2599 39 716 65.4 92 273 2708 36 438 74.3 0.89 (0.85 to 0.94)
Drug duration of action:
 Short acting 1 011 732 4973 440 142 11.3 1 011 732 4370 403 954 10.8 1.06 (1.02 to 1.10)
 Long acting 412 976 869 181 483 4.8 412 976 1341 165 450 8.1 0.60 (0.55 to 0.65)